| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from employee stock purchase plan | 365 | 365 |
| Net cash provided by financing activities | 727 | 379 |
| Net decrease in cash, cash equivalents and restricted cash | -15,824 | -154,738 |
| Cash and cash equivalents at beginning of period | 229,117 | - |
| Cash and cash equivalents at end of period | 213,293 | - |
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)